Five things for pharma marketers to know: Tuesday, July 26, 2016

Five things for pharma marketers to know: Tuesday, July 26, 2016

Sales of Gilead's HCV drugs fall; the DNC policy platform criticized price gouging; Janssen partners with Bristol-Myers Squibb on Opdivo combo drug

Huntsworth Health revenue rose 18% in the first half of 2016

Huntsworth Health revenue rose 18% in the first half of 2016

Red, a Huntsworth agency, also counted Sanofi as a new client.

M Booth supports Leukemia & Lymphoma Society's Light the Night campaign

M Booth supports Leukemia & Lymphoma Society's Light the Night campaign

The nonprofit is dedicated to curing blood cancer.

GSK Consumer Healthcare to prioritize digital after agency review

GSK Consumer Healthcare to prioritize digital after agency review

Now that it has consolidated its global agency roster, GSK Consumer Healthcare aims to increase digital marketing efforts.

Five things for pharma marketers to know: Monday, July 25, 2016

Five things for pharma marketers to know: Monday, July 25, 2016

Darzalex may interfere with blood testing; Kaine scrutinized for ties to pharma; medical societies are in support of bill exempting CME reporting

Five things for pharma marketers to know: Friday, July 22, 2016

Five things for pharma marketers to know: Friday, July 22, 2016

Herceptin biosimilar meets endpoint in clinical trial; Roche plans to launch five new drugs over the next year; government seeks to block insurer deals

Biogen ends Tecfidera DTC campaign, citing prescriptions

Biogen ends Tecfidera DTC campaign, citing prescriptions

The drugmaker had launched the campaign for the multiple sclerosis drug in 2015.

Five things for pharma marketers to know: Thursday, July 21, 2016

Five things for pharma marketers to know: Thursday, July 21, 2016

The FDA approves generic versions of AstraZeneca's Crestor; Biogen CEO steps down; drugmakers race to develop smart inhalers

Five things for pharma marketers to know: Wednesday, July 20, 2016

Five things for pharma marketers to know: Wednesday, July 20, 2016

Spending on CME rose in 2015; the FDA approves Valeant's Relistor; the Justice Department aims to block insurer merger

Novartis ups marketing investment in Entresto, by $200 million

Novartis ups marketing investment in Entresto, by $200 million

One oft-cited challenge to Entresto's adoption has been prior authorization requirements.

OPINION

Email Newsletters